Press Releases
2025 – Press Releases
NetraMark to Host Shareholder Conference Call to Discuss Business Momentum
April 10, 2025 | NetraMark Holdings | Join Call on Tuesday, April 15 at 4:00 – 4:30pm EST
NetraMark and Worldwide Clinical Trials Announce Agreement to Transform Clinical Trial Design with AI-Powered Insights
April 3, 2025 | NetraMark Holdings
NetraMark Strengthens Financial Position with $1,853,054 Raised from Warrant Exercise
March 10, 2025 | NetraMark Holdings
NetraMark Unveils AI Driven Insights for Major Depressive Disorder and Schizophrenia at ISCTM Conference
March 5, 2025 | NetraMark Holdings
NetraMark and the Ontario Brain Institute Partner to Advance AI-Powered Neuroanalytics for Major Depression Research
Feb 25, 2025 | NetraMark Holdings
NetraMark to Present Novel AI-Based Clinical Trial Treatment Separation Tools at ISCTM Annual Meeting
Feb 18, 2025 | NetraMark Holdings
NetraMark launches NetraAi 2.0: advancing clinical trial analysis with ai-powered insights
Feb 12, 2025 | NetraMark Holdings
NetraMark provides business update
Feb 4, 2025 | NetraMark Holdings
2024 – Press Releases
NetraMark strengthens financial position with $1,161,000 raised from warrant and stock option exercise
Dec 12, 2024 | NetraMark Holdings
Oncology commercialization leader P.J. Haley to join NetraMark board of directors
Oct 09, 2024 | NetraMark Holdings
NetraMark provides q3 business update and highlights progress
Aug 20, 2024 | NetraMark Holdings
NetraMark's ai-based clinical solution identifies novel lung and colon cancer biomarkers and patient subpopulations
April 10, 2024 | NetraMark Holdings
NetraMark provides business update and highlights progress
April 02, 2024 | NetraMark Holdings
NetraMark To Present New Data Highlighting The Utility Of Its AI Based Clinical Solution In Identifying Parkinson's Disease Associated Biomarkers At AD/PD™ 2024
February 29, 2024 | NetraMark Holdings
NetraMark To Present New Data Demonstrating The Power Of Its AI Based Technology To De-Risk Neurology Clinical Trials At ISCTM Annual Meeting
February 15, 2024 | NetraMark Holdings
NetraMark's Generative AI Discovers Novel Rare Disease Drug Targets and Unique Patient Subpopulations That Could Substantially Improve Clinical Trial Success Rates
January 16, 2024 | NetraMark Holdings
NetraMark expands team with the addition of industry veteran
Dec 11, 2024 | NetraMark Holdings
NetraMark to present at the 2024 cantech letter conference in toronto, on
Oct 02, 2024 | NetraMark Holdings
NetraMark announces collaboration agreement with nimh to analyze clinical trial data on the use of ketamine in psychiatric disorders
June 10, 2024 | NetraMark Holdings
NetraMark announces shareholder meeting results
April 05, 2024 | NetraMark Holdings
NetraMark signs contract with pharmaceutical company to deliver clinical trial insights regarding efficacy and placebo response
March 12, 2024 | NetraMark Holdings
NetraMark Signs Fourth Contract With Large Biopharmaceutical Company To Enhance Clinical Trial Insights
February 27, 2024 | NetraMark Holdings
NetraMark Announces Launch Of The Netra AI Lab
February 12, 2024 | NetraMark Holdings
NetraMark signs a pilot collaboration agreement with a top 5 pharmaceutical company
Dec 09, 2024 | NetraMark Holdings
NetraMark expands product offerings to address core clinical trial challenges and improve market access success
Sept 11, 2024 | NetraMark Holdings
NetraMark to introduce the treatment attitude profile (tap™) scale for placebo response persona discovery using its netra ai technology at the 2024 ascp annual meeting
May 28, 2024 | NetraMark Holdings
Pharmaceutical industry veteran joins NetraMark advisory board
April 04, 2024 | NetraMark Holdings
NetraMark's Ai-based clinical solution identifies parkinson's disease subtypes linked by mitochondrial, microbiome and immune signaling
March 11, 2024 | NetraMark Holdings
NetraMark's AI Based Technology Identifies Significant Drivers Of Efficacy And Placebo Responses And Has Potential To Improve Success Rates For Clinical Trials Of Psychiatric Medications
February 26, 2024 | NetraMark Holdings
NetraMark Signs Third Contract With Large Biopharmaceutical Company to Enhance Clinical Trial Insights
January 30, 2024 | NetraMark Holdings
2023 – Press Releases
NetraMark Signs Two Contracts With Large Biopharmaceutical Company To Enhance Clinical Trial Insights
December 20, 2023 | NetraMark Holdings
NetraMark Signs Master Service Agreement With a Large Biopharmaceutical Company
October 31, 2023 | NetraMark Holdings
NetraMark Private Placement – Press Release Clarification
September 15, 2023 | NetraMark Holdings
NetraMark Announces Shares for Debt Settlement
July 5, 2023 | NetraMark Holdings
NetraMark Closes Second and Final Tranche of Private Placement
June 14, 2023 | NetraMark Holdings
NetraMark Announces Increase to Private Placement Financing
June 6, 2023 | NetraMark Holdings
NetraMark Selects Finn Partners As Its Public Relations Agency Of Record
November 20, 2023 | NetraMark Holdings
NetraMark Signs Master Service Agreement With a Large Biopharmaceutical Company
October 31, 2023 | NetraMark Holdings
NetraMark Announces Private Placement Financing
September 11, 2023 | NetraMark Holdings
NetraMark Enters into Advisor Agreement
June 22, 2023 | NetraMark Holdings
NetraMark Closes First Tranche of Private Placement
June 9, 2023 | NetraMark Holdings
NetraMark Announces Private Placement Financing
June 1, 2023 | NetraMark Holdings
Pharmaceutical Industry Veteran Joins NetraMark as Chief Medical Officer Joins
November 7, 2023 | NetraMark Holdings
NetraMark Closes Private Placement Financing
September 19, 2023 | NetraMark Holdings
Pharmaceutical Industry Veteran Joins NetraMark Advisory Board
July 19, 2023 | NetraMark Holdings
NetraMark Announces Engagement of ARU Global Inc.
June 21, 2023 | NetraMark Holdings
NetraMark Announces Uplist to the OTCQB Market
June 7, 2023 | NetraMark Holdings
NetraMark to Attend American Society of Clinical Oncology Conference in Chicago
June 1, 2023 | NetraMark Holdings